Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Endeavour Silver Corp (EXK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Endeavour Silver Corp — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $223.46 (market cap $29.60B), while Endeavour Silver Corp trades at $10.61 (market cap $3.14B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 9.4× Endeavour Silver Corp's market cap, and Endeavour Silver Corp is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | EXK | |
|---|---|---|
Market Cap | $29.60B | $3.14B |
Sector | Health | Basic Materials |
52-Week High | $491.22 | $14.12 |
52-Week Low | $205.48 | $5.31 |
Enterprise Value | $27.56B | $3.14B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $222.54, up 2.56% today, amid a bearish technical signal with support at $218 and resistance at $223. The company reported strong revenue growth to $3.71B in 2025 and turned profitable with net income of $313.75M, though recent Q2 2026 earnings missed estimates. Analyst consensus remains bullish with a $370.07 price target, but multiple law firms are investigating potential securities fraud, creating near-term uncertainty.
The outlook is mixed: robust fundamentals and analyst support suggest long-term upside, but legal risks and recent earnings volatility pose significant headwinds. Investors face tension between strong profitability metrics and heightened sentiment risks from ongoing investigations.
Endeavour Silver (EXK) trades at $10.60, up 3.52% today, with strong technical momentum and bullish analyst sentiment. The company shows improving fundamentals with Q1 2026 earnings beating expectations and revenue growth projected from $468M in 2025 to $737M in 2026. Recent news highlights operational expansion, including the Terronera mine ramp-up and a new $25M credit facility, supporting future growth in silver and gold production.
Outlook is positive with 78.6% analyst buy ratings and a $15.50 consensus price target offering 46% upside. Key risks include execution of mine expansions, commodity price volatility, and the company's transition to profitability after a 2025 net loss. The stock presents a growth opportunity if operational targets are met, though investors should monitor quarterly earnings consistency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Endeavour Silver Corp
Endeavour Silver is a mid-tier precious metals mining company. It operates silver-gold mines in Mexico and is focused on growing its production and reserves through exploration and the development of new mining projects.
Read more on EXK →
